Thank you for joining, everybody. If you're not aware, we had a small change. Thomas couldn't make it, unfortunately, for family reasons, so we got Jean-François Toussaint, who heads the vaccines R&D at Sanofi. Thank you, Jean-François, for joining us.
My pleasure.
What I was going to do is sort of go a little bit broad on the topics before we sort of drill into the Sanofi vaccines R&D, just because the organization has gone through changes. So, can you talk about how the significant management changes this year, from your perspective, what do they mean? What have they done?
Yeah. Indeed, we went through quite a few changes, starting with the change of CEO and the arrival of Belén Garijo. For those who don't know Belén is, I would say, quite a pragmatic CEO. She's obsessed by patients and value. Actually, direction we get from her are very clear. Focus your energy on everything that contribute to the growth, contribute to the pipeline, or contribute to the evolution of the culture towards a high-performance culture. That's really what Belén brings. Of course, you have seen that she's also quite decisive. There were quite a few decisions made on the pipeline, and mainly the pharma R&D pipeline, where assets that had positive phase III but would not make the difference on the market were discontinued, because they would not be competitive from a commercial point of view.
Also decisive in terms of the ExCom. The ExCom has been changing quite a bit within Sanofi. And decisive as well in terms of her collaboration. She renewed or extended the collaboration with Regeneron on a couple of molecules, so was one of her first actions, and more to come, obviously, down the road. But also what seems very clear is that she has already identified which are the three therapeutic areas where she wants to play. I&I, so immunology and inflammation, is one, without surprise. Rare diseases is another one. And vaccine is confirmed as an important growth driver for Sanofi. So, that's what I can say. Of course, more to come, but for these three therapeutic areas, she's very clear she wants us to play there because she sees an opportunity, as we do.
Got it. And maybe just to follow up on that, like you said, there's been some pruning of the pipeline, but I don't think we've seen any reprioritization within vaccines. Is that a process or?
Good question. Obviously, for vaccines, we have a side R&D. So, we are not reporting into the pharma R&D. We're reporting into Thomas Triomphe, the Executive VP for vaccines. And actually, we've been actually prioritizing the pipeline quite a bit over the last few years. We terminated a couple of projects. An example, we had good result in flu mRNA. So, we invested in mRNA. We had good result in flu mRNA, result comparable to our competitors, but we felt mRNA will not make the difference in flu. We decided to discontinue. So, that's probably one of the reason why. Now, never say never. Of course, we keep generating data.
We have accelerated data generation in vaccine R&D, and as soon as data come, if we don't like them, if we believe the asset will not make it, we'll terminate it. So, it's an ongoing process in vaccines.
Okay. Helpful. Thank you. Another big-picture question. Obviously, we've seen the Moderna melanoma data at ESMO. As a head of vaccines, how do you react to that data?
Yeah. First, I'm very happy because I would say vaccines are usually underappreciated in terms of what they can do as a modality. So, I believe it's true in oncology, but it can be true in other areas as well. Of course, the multiple failures over the last three decades in cancer vaccine was not helping there. Now seeing a success is great. On the top of that, it's wonderful news for patients suffering from melanoma who now have an intervention that can increase the efficacy of checkpoint inhibitors. Now, the key question I have as head of vaccine R&D, can I play there? Certainly, we have developed a competitive mRNA platform. We have all the signals. We've shown efficacy in RSV. We've shown very good result in H5 pandemic. So, we have the mRNA platform that we need to play there.
But it's not only about mRNA platform. It's about how you select your neoantigens and being committed to oncology, which, as you understood, is not yet the case within Sanofi, and Belén was alluding to the fact that oncology may not be a priority area. So, while we have some of the toolbox available to play in cancer vaccine, I'm not convinced we're going to play there. So, if we don't play there might be opportunity to give access to a platform to someone who want to test it for cancer vaccines so that we can help someone and create value with the platform as well.
Got it. Very clear.
If there are any candidates, raise your hand.
A question on business model setup in vaccines. On the one hand, this is an area where few companies are active. It's genuine global scale, vaccines, but there is a degree of innovation as well. As we think about vaccines going forward, do you think this remains a sustainable competitive advantage as being one of the biggest of the biggest, or is this going to be an industry where there's going to be a shift towards innovation by smaller players rather than scale?
I would say both, Michael. I think if you want to have an impact in a flu season, for example, you still need to be able to fill 100 million of syringe and supply them in two months to the market. That is scale, and only scale can offer you that. So, scale is important. Vaccines remain capital-intensive. If you want to develop a vaccine and launch it very quickly after, you need to have existing infrastructure so that you don't have to build a new facility every time. So, I think scale is important. Scale at commercial level as well. I take the example of Dynavax. It's not lost on you that we acquired Dynavax last year. We had projection to grow the business with HEPLISAV-B within Sanofi, and actually, we are beyond the projection we had initially.
Dynavax, HEPLISAV-B, in the hands of Sanofi, is doing better than what we assumed, and we had already assumed an upside. That upside is because of scale, because of the portfolio that we have. Now, it's true that for a couple of years, Sanofi had lost the innovation engine in vaccines, and that's why we missed the train on a couple of vaccines, like HPV, like Pneumo, and that's why five years ago, we decided, "No, we need to reinvest. We need to rebuild the pipeline." I'm happy to see the progress we're making, and now we have a couple of assets that can make the difference, contribute to the growth, but you cannot remove the foot from the innovation gas pedal. Otherwise, you become irrelevant.
Got it. If we think about the vaccines market in the sense of redistribution of an existing defined market, so the improvement upon something that's there already, but it's just moving shares from one player to another, as opposed to actually growing the vaccines market. When you take a step back and you zoom out, what areas are actually genuinely expanding the market as opposed to fighting for share?
Yeah. No, I like the question because from your side, it's a relevant question. Will the vaccine market keep growing? From my side, being at Sanofi, and actually, because we are not in a couple of very rewarding segments, I still believe for us, Sanofi, it's important that we play in pneumococcal, that we play in RSV vaccine for all the adults, and take market share. Of course, it may not grow the market, but if we have the right product, we will be able to take some share. Now, there is opportunity to grow the market. Grow the market, I would say, by increasing immunization rate. Still, there are some older adult vaccines that are underused, and for which we need to do a better job. Combination vaccine might be a solution.
We're developing flu and COVID combo vaccine to increase number of people who have a COVID vaccine without the reactogenicity, the side effect that comes with mRNA COVID vaccine. Or RSV/hMPV, another vaccine where we want to double the medical value so that actually we have a more compelling value proposition and increasing the market. I would say that's mainly the incremental innovation. There is a disruptive innovation new segment, and there at Sanofi, we have a couple of shots on goal. We have an acne vaccine candidate that is in phase II as we speak. Still a bit of time. Yes, it takes a bit of time to get the proof point whether it works or not, but this is a vaccine that, if it works, could be growing the market in vaccines.
We have a chlamydia vaccine, and I know other companies have innovative vaccine as well that could contribute to growing the overall size of the pie.
Yeah. Maybe follow up here. If there's an area, let's say rabies vaccines, right? There seems to be a sort of a reinvigoration of that market, certainly in the U.S. right now. If that happens, how do you react to that? Is that an area where you kind of go, "Okay, maybe we find a BD target to play?" Is that an area where you go have a look in a pipeline, develop something? Like, how do you balance immediacy versus longer term differentiation?
Yeah. So, I would say we look at the different scenarios. We look at the core competencies we have. Can we play? Can we play better organically developing a vaccine candidate, bringing it as quickly as possible to the market? Or is there an opportunity for us to partner because it would take too much time, or we don't have the core competencies we want? Now, you took rabies. I'm not sure whether it was random or not, but actually, we're on the verge of getting approval for a new rabies vaccine, an improved rabies vaccine. So, that would not be a field we would do BD. Rabies vaccine has been developed decades ago with very old process using a lot of animal-derived components, and we've modernized the process. We believe it the right thing to do, having a vaccine produced using modern manufacturing practices, also ensuring sustainability of supply.
For that one, of course, it will be cannibalization of our own sales, but it is the right thing to do for patients and for supply sustainability. Not everybody has done that, so potentially down the road, that will be a competitive advantage as well.
Yeah. Okay. And then if you sort of look at your pipeline, to meaningfully change the trajectory, and I think you partly answered it, of the vaccines business, what needs to work to really make a difference to the longer term trajectory of the vaccines business?
Yeah. I would probably refer to the vaccine, I believe, that have a fair chance of making it or being completely transformative. So, on one hand, with the flu plus COVID combo, I believe we have a highly differentiated best-in-class flu vaccine. Novavax is a highly efficacious, well-tolerated COVID vaccine. Combining them together is not the greatest invention on earth, but it's an innovation that can benefit patient and grow the business for us. That one is one that we started phase III recently and can be a growth driver. RSV, hMPV, I alluded to that. So probably the size of the market today, when you look at GSK, Pfizer, Moderna with RSV standalone, it's $ 2 billion. We want to come with RSV plus hMPV, so doubling the medical value by adding another component. And so far, we are poised to be a first in class with that one.
So again, increasing the value for patient and the value of the product, and certainly contributing growth to Sanofi. We have a pneumococcal PCV21, so pneumococcal conjugate vaccine in phase III in the pediatric population, six ongoing phase III trial. They will read in 2027, so quite exciting. And again, it's a big established market, so should we succeed phase III and enter that market, that can also contribute meaningfully. Then there are more wild cards. When we did the Dynavax deal, we got access to a shingles vaccine candidate, adjuvanted one. We have good data in young adult. We need to see the data in the older adult. We got it for free, so if it works, it fills the pipeline. If it doesn't work, then we'll see whether we can fix it or whether we need to discontinue. I'm excited about the acne vaccine.
I mentioned that before. So we're progressing. We are having a large phase II trial, 800 volunteers. So in a couple of years, we know whether it can work, whether we can impact the course of acne disease with a vaccine. And if that works, that could be highly rewarding. So these are the kind of example of asset that could contribute to our growth. Not everything will work. As usual in R&D, we had our share of failures like everyone. But if we have two or three that works, it could contribute meaningfully to our growth.
Got it. Maybe a follow-up. GSK is running some studies for their shingles vaccine, looking at cardiovascular outcomes and dementia. Do you think there is more of that kind of evidence out there that vaccinations actually go beyond the primary target?
Yes. I think we have been, to some extent, pioneers in that within Sanofi. We have run a real-world evidence trial to show that actually flu vaccine and actually a differentiated flu vaccine, Fluzone High-Dose, could reduce the risk of cardiovascular disease, stroke, abnormal glycemic events. We have shown that already five years ago, and no later than last year, we did a real-world evidence study with 450,000 volunteers to confirm actually the benefit. I like that others are doing it as well. I think there is a dementia, risk of dementia decrease with a shingles vaccine, actually with two shingles vaccine, the one from Merck and the one from GSK, cardiovascular as well. Yes, I believe, it is like acne. I believe there are many more diseases that are originating from an infectious disease than what we thought.
If we can impact them early on, we could potentially impact the course of some chronic diseases or diseases that were positioned as chronic before. Yes, I think vaccine is undervalued, and as a modality, there is room to use it beyond the classical infectious disease.
Yes. If we pivot to RSV, obviously, you have been very successful with Beyfortus, but there are alternative approaches to RSV as well. What are the learnings from it, sort of going passive versus non-passive immunization?
Yeah. First, very happy that you mentioned it. Very happy that you mentioned BEYFORTUS that we co-developed with AstraZeneca. That one has had a massive public health impact, certainly. We have nurses, we have doctors telling us, "We don't see nurses quitting the hospital during the winter outbreak because they keep a normal life and don't want to quit the job." That's the kind of impact we can have with vaccination when you can prevent an outbreak. BEYFORTUS, very happy about the performance, both on efficacy in the phase III, the safety profile, and the effectiveness that we have shown consistently actually in more than 20, 30 countries, always in the same range. Very happy about that. Yes, there is another approach that is maternal immunization. Did not allude to that, but indeed vaccinating the mother and the mother transmitting the antibodies to the infant.
I think the countries that made the effort to compare the two interventions see that both are efficacious. Both can bring effectiveness, can reduce the risk of hospitalization. The big difference is that when you give a monoclonal antibody, you have a much better persistence, so you have a high efficacy for at least six months and probably later. When you look at maternal immunization, you have a good protection for the first three months, and then it's waning quite quickly. The second thing is that maternal immunization, you cannot decide when you give it. You give it during the third trimester, and if the baby is born in a season, he has some benefit. He's not born in a season, he doesn't get benefit. With a monoclonal antibody, we give it to the baby at birth or when he or she enters the season, so we can better time.
From a durability point of view, efficacy point of view, and convenience and when to administer, I think monoclonal is probably a better approach for RSV. Of course, what is true for RSV may not be true for other diseases. Pertussis, for example, the risk is mainly in the first three months. There is no seasonality or less of a seasonality, so pertussis maternal immunization is the right approach.
Got it. Then going into sort of combinations, you acquired Vicebio, that gave you hMPV. There's a VXB-241 , you've got PIV3. Is this going to go into a broader- combination vaccination approach? Is that sort of the end game, to go as broad as possible with one vaccine?
I think it's too early to say. Maybe if I go back to Vicebio acquisition, because we've been talking about hMPV for five years. Since I joined, December 1st, 2021, we were talking about RSV plus hMPV and how it can increase medical benefit and increase the value. We have actually two candidates that are RSV plus hMPV, one based on mRNA, and the other that we acquired from Vicebio. So, Vicebio doesn't bring only hMPV, it brings RSV plus hMPV in a format where we expect boostability of the immune response, which has been a shortcoming of the competitive vaccine, and in a format where we can keep the vaccine stored in a liquid formulation in a prefilled syringe in a fridge. Whereas the other vaccine, competitive vaccine, are either frozen or needs to be reconstituted.
That's a differentiation that we see with Vicebio, compared to mRNA or competitive vaccine. Of course, we don't have all the data yet, and we'll decide which is the best approach. Vicebio brings RSV, hMPV, and PIV. We also had with mRNA, RSV, hMPV, PIV. Now, the three, RSV and hMPV are very similar to each other, so these are too obvious to be combined. Very similar, same immune response that we induce, same seasonality. So I think these two, that's for sure, needs to be together in our view. Should we add the PIV? Actually, there are multiple PIV, one, two, three, four, five. Which to add? The seasonality is a bit different, the immune response is a bit different. PIV is less certain in my view, but RSV, hMPV is the obvious one, and we want to be first there.
Got it. Then maybe, because pneumococcal is obviously important, how should investors think about PCV21 versus PCV20, higher valency? There's a few platforms out there. Talk about the plan here and competitive profile and timelines.
Yeah. Our view is maybe simplistic, but I believe it's the right one. We understand that for a very key vaccine like pneumococcal, agencies are unlikely to give preferential recommendation. They want to have more than one supplier, and it's a complex biologics, more than 20, 21 different components. If you look at today, the two vaccines in the market in U.S., you have a PCV15, 15 component, 20 component, and actually they have the same recommendation. Meaning, yes, there is tolerance from the public health maker to have a slightly lower valency, to ensure supply and to ensure competition. If we extrapolate that, it means that 21 will not be differentiated from 20, and we are not counting on it, let's be clear. We will never get preferential recommendation, or a competitor will not get it either. But we discussed scale.
We discussed the importance of having a pipeline. We are a leader in pediatric vaccines, with the two hexavalent fully liquid that we have. Having a pneumococcal that is part of the recommendation, that we can sell and that we can also combine with other vaccine in the pipeline, should help us gaining some shares in an existing market. Our other platform coming with higher valency, we will also start our next generation vaccine with a higher valency. Our platform already embed two different carrier proteins. We know one of the competitors decided to include a new carrier. We had it already in the PCV21 so that we can hopefully increase the scale. For the next generation data to come, it is too early. The PCV21, the phase II data were good, so hopefully the phase III will confirm that.
Got it. Then maybe in the last three minutes, I want to talk about acne. Just give us an update on timing. What gave you confidence that this vaccination candidate can meaningfully alter the biology? Then what I am more interested in is actually, the implications seem to be broader than that, right? You seem to be going after vaccines that can go after microorganisms, which I think is different. Can you cover that in two and a half minutes?
Yeah, sure. I will try to be brief, but I am very excited about this program as well. Indeed, when we look at the biology of acne, we know bacteria is exciting the immune system and that is causing inflammation. So acne is an inflammatory disease. Long story short, we have a vaccine candidate that try to neutralize the bacteria that goes deep in the skin, neutralize the toxin that the bacteria produce, and limit inflammation, and to some extent, cure. We know bacteria plays a role because if you use antibiotic, it works, but you stop using antibiotic, it come back. So that is why a vaccine could be doing the job. The vaccine is currently in phase II, and we have expanded the size of the phase II already a year ago. So we had a phase II that was initially 200 volunteers.
We wanted to have a robust signal before going to phase III, so we have expanded to 800. So it will take a bit more time to get the result, but once we have them, we will know with confidence whether it works or not, if there are subpopulations where it works, and what to do in phase III. So that will be the status, and 2028 is a date that you can pencil in your calendar. You are completely right. What we are after here is acne, and acne on its own can be very rewarding, but we also want to have a proof of concept that we can dampen inflammation by tackling a pathogen.
Yeah.
I think it's obviously a proof of concept that we're waiting for. If it's positive, we have ideas on how to push on the accelerator and include, develop vaccine for other virus and bacteria that are triggering inflammation, instead of dealing with inflammation with monoclonal antibody, anti-cytokine, et cetera, trying to tackle the root cause. That's what we're aiming for here. It's bigger than the vaccine itself, but the vaccine can be big on itself as well.
Got it. In the last 40 seconds, just a sort of catalyst roadmap in vaccines over the next 12 to 18 months. What are we looking for?
Yeah. We started phase III for the flu COVID combo, so it's an immunogenicity study, so hopefully we should have result in the next 18 months. We expect the pneumococcal phase III results indeed next year, so that's also something that will be important. You can expect potentially one of the other readouts on the pandemic influenza. You can expect also We started a phase II-B with RSV plus hMPV, because we believe it makes sense to have both, but it doesn't mean that the endpoint we have for RSV is immediately transposable to hMPV, and the phase III will be expensive. Our view was, let's do a phase II-B, let's monitor efficacy, let's see what endpoint is suited for hMPV before starting phase III. We started that trial, and it's a phase II-B, and it's a seasonal disease.
Hopefully in 18 months, at least I will have data. I'm not sure I will share them with you. That's a different story. But normally, I should have data there, and you will see whether I'm progressing to phase III or not with that asset.
Got it. Jean-François, thank you.
My pleasure. Thank you.